BMO Capital Cuts Price target on Valeant Pharma (VRX) Following Poor 3Q Legacy Business Performance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Valeant Pharmaceuticals Reports Third Quarter 2015 Financial Results
October 19, 2015 6:00 AM EDTLAVAL, Quebec, Oct. 19, 2015 /PRNewswire/ --
2015 Third Quarter Results
Total Revenues of $2.8 billion; an increase of 36% over the prior year despite negative foreign exchange impact of $172 million Same store sales organic growth of 13%; 5th consecutive quarter of > 10% organic growth, driven by: Continued outperformance of U.S. businesses, particularly dermatology and contact lens Strong results in China (23%), South Korea (15%) and Mexico (10%) Total company growth was 8.2% volume and 4.4% price U.S. branded pharmaceuticals growth was 18.8% volume... More